Drug intelligence / Profile preview

Dex2

Development stage: Phase 2
Lead developer: Gustave Roussy
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

Dex2 is a second-generation immunotherapy composed of tumor antigen-loaded dendritic cell-derived exosomes. Developed by Gustave Roussy and Curie institutes, it is designed to activate both innate and adaptive immunity, including T and Natural Killer cell effector functions. It is being investigated as a maintenance immunotherapy for patients with advanced unresectable non-small cell lung cancer who have responded to induction chemotherapy.

Other names: dendritic cell-derived exosomes

Beyond the preview

Go deeper on Dex2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dex2.

Explore the full profile